Rockline Wealth Management LLC Buys 85 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Rockline Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,529 shares of the medical research company’s stock after purchasing an additional 85 shares during the quarter. Rockline Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $795,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. International Assets Investment Management LLC raised its holdings in Thermo Fisher Scientific by 76,051.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company’s stock valued at $876,152,000 after buying an additional 1,414,556 shares during the last quarter. FMR LLC lifted its holdings in shares of Thermo Fisher Scientific by 19.7% during the third quarter. FMR LLC now owns 7,877,459 shares of the medical research company’s stock worth $4,872,761,000 after purchasing an additional 1,294,453 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Thermo Fisher Scientific in the third quarter valued at $254,412,000. Lindsell Train Ltd bought a new position in Thermo Fisher Scientific during the 4th quarter worth $211,858,000. Finally, Franklin Resources Inc. lifted its holdings in Thermo Fisher Scientific by 5.7% during the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company’s stock worth $2,935,377,000 after buying an additional 262,062 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the transaction, the chief executive officer now owns 33,608 shares in the company, valued at approximately $18,757,296.96. This represents a 22.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 29,000 shares of company stock valued at $15,859,540 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday. Bank of America reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Citigroup boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a report on Friday. Bernstein Bank lifted their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $658.00.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $593.38 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market cap of $226.97 billion, a PE ratio of 35.90, a price-to-earnings-growth ratio of 4.06 and a beta of 0.77. The stock’s fifty day simple moving average is $541.37 and its two-hundred day simple moving average is $571.18.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.44%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.